Genexis Group presents Q2 2025 financial report

Genexis Group’s net sales Q2 2025 were EUR 19.1 million, EUR 1.2 million higher than Q2 2024, and EUR 0.9 million higher than the previous quarter. Order intake was low at EUR 12.7 million, EUR 3.3 million lower than Q2 2024.

The consolidated adjusted EBITDA of Q2 2025 was EUR 1.5 million, EUR 0.7 million lower than Q2 2024, and the operating cash flow after investment activities in Q2 2025 was negative at EUR -1.6 million. 

”We have during the second quarter experienced higher geopolitical uncertainty and decline in order intake. All though our revenue development in Q2 grew year-on-year and quarter-on-quarter, we experienced decreasing margins. Our business engagement in the North America market continues to grow, with existing customers placing new orders and new customer wins on the horizon. Opportunities generated by our Heimgard CPE acquisition have started to convert. This while our core business and our core markets were relatively stable.” says Genexis Group CEO Gerlas van den Hoven. 
 
You find the complete report at https://genexis.eu/investors/#financial 

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR TO U.S. PERSONS OR IN OR INTO ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL.